SCHEMBL14728265

SCHEMBL14728265

N#Cc1c2c(c(Cl)n3c1nc1ccccc13)C1CCC2C1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPSR1 Q6W5P4 6/20 0.53
MAPT P10636 4/20 0.53
SMN1; SMN2 Q16637 4/20 0.53
LMNA P02545 4/20 0.53
RAB9A P51151 2/20 0.53
NPC1 O15118 1/20 0.53
MDM2 Q00987 1/20 0.53
HSP90AA1 P07900 1/20 0.52
KDM4E B2RXH2 10/20 0.51
ALDH1A1 P00352 8/20 0.51
GAA P10253 4/20 0.51
POLB P06746 4/20 0.51
GLA P06280 3/20 0.51
XBP1 P17861 1/20 0.51
KMT2A Q03164 6/20 0.50
HPGD P15428 4/20 0.50
HTT P42858 3/20 0.50
RXFP1 Q9HBX9 2/20 0.47
NCOA3 Q9Y6Q9 1/20 0.47
TDP1 Q9NUW8 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14728488 0.81 NPSR1 (0.53) NPSR1MAPTSMN1; SMN2LMNAKDM4E
SCHEMBL6312223 0.79 NPSR1 (0.60) NPSR1MAPTSMN1; SMN2LMNARAB9A
SCHEMBL14728486 0.79 MAPK1 (0.46) NPSR1MAPTSMN1; SMN2LMNAKDM4E
SCHEMBL14728490 0.79 MAPK1 (0.46) NPSR1MAPTSMN1; SMN2LMNAKDM4E
SCHEMBL14728489 0.79 ALDH1A1 (0.50) NPSR1MAPTLMNAKDM4EALDH1A1
SCHEMBL6310420 0.78 NPSR1 (0.74) NPSR1MAPTSMN1; SMN2LMNARAB9A
SCHEMBL14728261 0.76 KDM4E (0.40) NPSR1MAPTSMN1; SMN2LMNARAB9A
SCHEMBL14728491 0.75 ALDH1A1 (0.45) NPSR1SMN1; SMN2LMNAKDM4EALDH1A1
SCHEMBL14728575 0.74 KDM4E (0.46) NPSR1LMNAKDM4EALDH1A1GAA
SCHEMBL30630102 0.73 KDM4E (0.62) NPSR1MAPTSMN1; SMN2LMNARAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8822688-B2 Imidazo[1,2-a]pyridine derivative ASTELLAS PHARMA INC. (JP) 2014-09-02 US disclosed
US-8822688-B2 Imidazo[1,2-a]pyridine derivative ASTELLAS PHARMA INC. (JP) 2014-09-02 US disclosed
US-20130053363-A1 IMIDAZO[1,2-a]PYRIDINE DERIVATIVE ASTELLAS PHARMA INC. (JP) 2013-02-28 US disclosed
US-20130053363-A1 IMIDAZO[1,2-a]PYRIDINE DERIVATIVE ASTELLAS PHARMA INC. (JP) 2013-02-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130053363-A1 IMIDAZO[1,2-a]PYRIDINE DERIVATIVE PDE4B, PDE4A, PDE4C NPSR1 2690/4885MAPT 411/4885SMN1; SMN2 2352/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.